文献速递神经肿瘤

立体定向激光消融临床使用模式:多中心前瞻性登记研究分析

Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry.
PubMed 文献 · World Neurosurg · 2018-05-14

基于LAANTERN前瞻性登记研究前100例患者,分析立体定向激光消融(SLA)的临床使用模式。适应证包括原发颅内肿瘤(48%,其中81%为高级别胶质瘤)、脑转移瘤(34%)、癫痫(16%)和其他(2%)。高级别胶质瘤中新诊断与复发/经治病变使用SLA的可能性相当,而脑转移瘤主要用于放疗/放射外科失败后(91%)。45%的SLA替代了手术切除,43%因病变无法常规手术到达。

要点

  • SLA主要适应证为高级别胶质瘤和脑转移瘤,分别占原发颅内肿瘤的81%和全部SLA的34%。
  • 高级别胶质瘤中新诊断(45%)与复发/经治(55%)使用SLA的可能性相当(P=0.54)。
  • 脑转移瘤中91%的SLA用于放疗/放射外科失败后,仅9%作为新诊断病变的初始治疗(P<0.001)。

核心结论

  • 在LAANTERN研究中,高级别胶质瘤和脑转移瘤是SLA的主要适应证。
  • 对于高级别胶质瘤,SLA在新诊断和复发/经治情境中使用频率相当。
  • 对于脑转移瘤,SLA通常用于复发情境。
  • SLA用于难以到达的病变或替代传统开放手术的可能性相当。

研究设计与样本

  • 前瞻性登记研究(LAANTERN登记),报告首批100例入组患者的数据。

主要发现

  • SLA的临床适应证包括原发颅内肿瘤(48%,其中81%为高级别胶质瘤)、脑转移瘤(34%)、癫痫(16%)和其他(2%)。
  • 高级别胶质瘤中,SLA用于新诊断病变占45%,用于经治/复发病变占55%(P=0.54)。
  • 脑转移瘤中,SLA用于放疗/放射外科失败后占91%,作为新诊断病变初始治疗占9%(P<0.001)。
  • 所有SLA手术中,45%替代了手术切除,43%因病变无法通过常规神经外科技术到达而实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic laser ablation (SLA), also termed laser interstitial thermal therapy, is a minimally invasive procedure that is increasingly used in neurosurgery. We wished to examine how and whether SLA is changing the landscape of treatment options for neurosurgical patients. METHODS: Patients undergoing stereotactic laser ablation were prospectively enrolled in the Laser Ablation of Abnormal Neurological Tissue (LAANTERN) registry. Data from the first 100 enrolled patients are presented here. RESULTS: Clinical indications for SLA include treatment of primary intracranial tumors (48%; 81% being high-grade gliomas [HGGs]), brain metastases (BMs, 34%), epilepsy (16%), and other (2%). For HGGs, SLA was equally likely used for newly diagnosed (45%) or previously treated/recurrent lesions (55%, P = 0.54). By contrast, SLA was predominantly used as treatment for BMs in which radiation therapy/radiosurgery had failed (91%), with only 9% of SLAs performed as initial treatment for newly diagnosed lesions (P < 0.001). Of all SLAs performed, 45% of the procedures were in lieu of surgical resection, with 43% performed because the lesion was not accessible by conventional neurosurgical techniques. CONCLUSION: HGGs and BMs are the leading indications for SLA in the LAANTERN study. For HGGs, SLA is equally used in the presenting or previously treated/recurrent setting. For BMs, SLA is typically used in the recurrent setting. SLAs are equally likely to be performed for difficult-to-access lesions or in lieu of conventional open surgery.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Rennert RC, Khan U, Tatter SB, et al. Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry. World Neurosurg. 2018. PMID: 29772367. doi:10.1016/j.wneu.2018.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。